Results 171 to 180 of about 20,250 (180)

Trametinib: a MEK inhibitor for management of metastatic melanoma

OncoTargets and Therapy, 2015
Iwona Lugowska, Katarzyna Kozak, Piotr Rutkowski   +2 more
exaly  

The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma

Expert Opinion on Drug Safety, 2018
Elisabeth Livingstone, Lisa Zimmer, Sarah Knispel   +2 more
exaly  

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

European Journal of Cancer, 2017
Andrzej Mackiewicz, John Haanen, Claus Garbe   +2 more
exaly  

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

Journal of Thoracic Oncology, 2017
Jean-Pierre Delord, Karen Kelly, Natasha Leighl   +2 more
exaly  

Trametinib for progressive pediatric low-grade gliomas

Journal of Neuro-Oncology, 2018
Christine Saint-Martin, Sébastien Perreault, Benjamin Ellezam   +2 more
exaly  

Adjusting for treatment switching in theMETRICstudy shows further improved overall survival with trametinib compared with chemotherapy

Cancer Medicine, 2016
Nicholas Latimer
exaly  

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma

Thyroid
Mark Zafereo, Jennifer R Wang, Naifa Busaidy   +2 more
exaly  

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of Oncology, 2015
J R Infante, J C Bendell, D Rasco
exaly  

Dabrafenib and trametinib for the treatment of non-small cell lung cancer

Expert Review of Anticancer Therapy, 2018
Ronan J Kelly
exaly  

Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma

Future Oncology, 2014
exaly